Collaborations: ImmunoGen, Inc.

Home

Company	\|	Date	\|	Type
		12/06		Option for Expanded Access to ImmunoGen's TAP Technology
		10/06		License for Broader Access to ImmunoGen's Humanization Technology
		8/06		Second extension of 7/03 research collaboration; release of ImmunoGen from presenting targets
		8/05		Extension of 7/03 research collaboration
		7/03		Research, development, and commercialization collaboration

		7/06		ImmunoGen, Inc. Grants Biotest AG Rights to Use ImmunoGen TAP Technology to Develop Novel Anticancer Therapeutics; ImmunoGen Has Opt-In Rights on Resulting Compounds

		5/06		ImmunoGen to develop commercial-scale manufacturing process for trastuzumab-DM1 (T-DM1) for Genentech; amendment of 5/00 HER2 agreement
		5/00		Right to use TAP technology with antibodies HER2

		12/05		Right to use TAP Technology with antibodies to an undisclosed target

		7/05		Right to use TAP technology with antibodies to an undisclosed target

		5/05		Renewal of 5/00 "right to test" agreement
		5/00		Right to test TAP technology

		4/05		Right to use TAP technology with antibodies to an undisclosed target

		10/04		Right to use TAP technology with antibodies to an undisclosed target

		2/02		Right to use TAP technology with antibodies to the prostate-specific membrane antigen

		11/01		Right to use TAP technology with antibodies to CD44 (or alternate)

		9/00		Right to test TAP technology
(formerly Abgenix)

Last updated January 3, 2008